# Compare Semax and Selank — Deep Dive Peptides

> A side-by-side comparison of two Cognitive & Nootropic research peptides — Semax and Selank — across peptide class, most-studied effects, evidence base, administration studied, regulatory status and key caution.

Where Semax and Selank converge, where they diverge, and how far the evidence behind each one actually reaches.

## The short version

This page lines up [Semax](/semax) and [Selank](/selank) on the dimensions that matter most when reading research peptides: what kind of molecule each one is, where it has been studied most, how strong that evidence is, how it was given in the studies, its regulatory standing, and its single biggest caution. The headline: both are synthetic heptapeptides sharing a C-terminal stabilizing tail, both originate overwhelmingly from Russian research institutions, and neither is approved by the FDA or EMA. Beyond those structural and geographic similarities they are genuinely different compounds with different primary mechanisms and different community use profiles. Semax leads with neurotrophin upregulation and neuroprotection; Selank leads with GABA modulation and anxiety relief. Neither compound is presented here with a human dose.

## The comparison matrix

| Dimension | Semax | Selank |
| --- | --- | --- |
| Peptide class | Synthetic ACTH(4-7) analog; stabilized heptapeptide (7 aa) | Synthetic tuftsin analog; stabilized heptapeptide (7 aa) |
| Most-studied in | Neuroprotection (cerebral ischemia), BDNF/NGF upregulation, cognitive task performance | Non-benzodiazepine anxiolytic; GABA-pathway gene expression; stress models |
| Evidence base (model) | Predominantly rodent; Russian clinical literature for stroke/TIA/cognitive impairment; no Western RCTs [2][3] | Predominantly rodent; small Russian clinical studies in anxiety-asthenic disorders [8][12]; no Western RCTs |
| Administration studied | Intranasal (primary); brain-penetration PK data at 2 min post-dose [6] | Intranasal (primary, clinical use); IP in some rodent studies |
| Regulatory / WADA status | Prescription drug in Russia/Ukraine; unscheduled research chemical in US; possible WADA S0 catch-all | Prescription anxiolytic in Russia; unscheduled research chemical in US; not specifically WADA-listed |
| Key caution | Narrow geographic evidence base; unknown drug interactions with stimulants and monoaminergic drugs [7] | Multi-pathway interactions (GABA + opioid + immune); self-treating anxiety delays clinical care |

## Peptide class

Both are synthetic heptapeptides (seven amino acids) with a C-terminal Pro-Gly-Pro stabilizing tail — this structural strategy is what makes each peptide metabolically more durable than its natural parent fragment. But their N-terminal cores are completely different: Semax's core is Met-Glu-His-Phe, the ACTH(4-7) fragment that gives it its hormone-derived cognitive and adaptive properties without the cortisol-releasing effect of full ACTH; Selank's core is Thr-Lys-Pro-Arg, the tuftsin tetrapeptide that gives it its immunomodulatory and anxiolytic character [8]. Two peptides that look superficially alike in their design logic are pharmacologically quite different.

## Most-studied in

Each peptide has a clear research home territory. Semax is studied most in models of neuroprotection — cerebral ischemia, spinal-cord injury [1][2] — and in the neurotrophins BDNF and NGF that underlie nerve-cell survival and plasticity [3][4]. The cognitive task performance evidence follows from this neurotrophic and neuroprotective base. Selank's research home is anxiety: it has been studied in rodent stress models [9], in gene expression assays focused on GABA-pathway modulation [10], and in limited human trials in anxiety-asthenic patients [12]. BDNF in the hippocampus appears in both stories [4][11], but for Semax it is the central mechanism and for Selank it is a supporting finding.

## Evidence base (model)

This is where the two converge more than they separate. Both compounds are supported primarily by rodent pharmacology from a geographically concentrated set of Russian research institutions. Western replication in independent randomized controlled trials is absent for both. The small Russian clinical studies that exist for each compound are largely published in Russian-language journals, with English abstracts only, limiting full methodological scrutiny. Selank's human evidence, if thin, is at least explicitly clinical in design (patients with diagnosed anxiety disorders [12]); Semax's human evidence is mostly neurological case series and EEG reports from stroke or cognitive-impairment practice rather than controlled trials. Neither compound has established efficacy in Western-standard human trial populations for any cognitive or anxiolytic indication.

## Administration studied

Both peptides are primarily studied and used intranasally — the route that takes advantage of nasal mucosal absorption to bypass first-pass metabolism and deliver peptides to the CNS more efficiently than oral administration. For Semax, intranasal pharmacokinetic data are available: after a single dose in rats, radioactively labeled Semax appeared in brain within 2 minutes, with roughly 80% arriving as intact peptide [6]. Intranasal Selank is the route used in clinical studies [12] and in community use, though formal human pharmacokinetics are not well characterized in mainstream literature. Neither has been studied extensively by intravenous or subcutaneous routes in published accessible work.

## Regulatory and WADA status

Neither Semax nor Selank is approved by the FDA or EMA for any indication. Both hold prescription-drug status in Russia (Semax for ischemic stroke, TIA and cognitive impairment; Selank as an anxiolytic for anxiety-asthenic disorders), but this registration does not confer approved status in Western countries. In the United States both are sold strictly as unscheduled research chemicals. On WADA's Prohibited List, Semax is not named explicitly but may fall under the S0 non-approved substances catch-all; Selank is not specifically listed but the same S0 reasoning could apply. Athletes under anti-doping rules should check GlobalDRO and consult the relevant authority before any use.

## Key caution for each

Each compound carries a defining caution. For Semax the key issue is the combination of a geographically narrow evidence base and poorly understood drug interactions: in rodent studies Semax strongly potentiated amphetamine-evoked dopamine release and inhibited serum enkephalinases [7], meaning combinations with stimulants, serotonergic drugs, or opioid-active substances have unstudied and potentially additive effects. For Selank the key caution is its multi-system pharmacological reach — touching GABA receptors, enkephalin signaling, monoamine turnover, and immune cytokine balance [8][9][12] — combined with the specific risk that using an unapproved research compound to self-treat anxiety delays proper clinical assessment and established treatment. The lesson across both: promising mechanisms, a single-region evidence base, and a safety profile that has not been independently characterized at scale.

---

Peer-reviewed research, carefully read — a literature digest, not a clinic or a vendor, and never a dose.